
Andreas L Marzinzik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7577843/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|---|---|------|-----------|
| 1 | Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors. RSC Chemical Biology, 2021, 2, 1661-1668. | 4.1 | 7 |
| 2 | Fragmentâ€Based Discovery of Nonâ€bisphosphonate Binders of <i>Trypanosoma brucei</i> Farnesyl Pyrophosphate Synthase. ChemBioChem, 2020, 21, 3096-3111. | 2.6 | 8 |
| 3 | Discovery of Potent and Selective Antibody–Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. ACS Medicinal Chemistry Letters, 2019, 10, 1674-1679. | 2.8 | 10 |
| 4 | Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. Journal of Medicinal Chemistry, 2018, 61, 8120-8135. | 6.4 | 275 |
| 5 | The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature, 2017, 543, 733-737. | 27.8 | 389 |
| 6 | Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 454-462. | 2.3 | 59 |
| 7 | Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nature Chemical Biology, 2010, 6, 660-666. | 8.0 | 110 |
| 8 | Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay. Journal of the American Chemical Society, 2010, 132, 7043-7048. | 13.7 | 95 |
| 9 | Library Design for Fragment Based Screening. Current Topics in Medicinal Chemistry, 2005, 5, 751-762. | 2.1 | 195 |